Drugs / HCW9218
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05322408 | Apr 2022 → Jan 2025 | cancer | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05304936 | Oct 2022 → Feb 2025 | — | ImmunityBio, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05145569 | May 2024 → May 2026 | ovarian cancer | Haider Mahdi | Withdrawn | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-04-03 | HCW Biologics | Results A Novel Immunotherapeutic Approach to Treating Aging-Associated Diseases hcwbiologics.com ↗
Subcutaneous Administration of HCW9218 Systemically Reduces Senescent Cells and Alleviates Senescence-Associated Secretory Phenotype Factors in Mice |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-04-03 | HCW Biologics | A Novel Immunotherapeutic Approach to Treating Aging-Associated Diseases hcwbiologics.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HCW9218 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05304936 ↗ |
| Action | Inhibit | “We hypothesize that HCW9218 will act as a senolytic by "trapping" excess TGF-β, therefore inhibiting its ability to promote senescence.” NCT05145569 ↗ |
| Modality | Protein / enzyme biologic | “HCW9218 is an immunotherapeutic comprising transforming growth factor-b (TGF-b) receptor II and interleukin (IL)-15/IL-15 receptor a domains.” NCT05145569 ↗ |
| Route | Subcutaneous | “administered as a subcutaneous injection” NCT05322408 ↗ |